WuXi Biologics (Cayman) Inc. (WXXWY)
OTCMKTS
· Delayed Price · Currency is USD
5.94
-0.09 (-1.49%)
Feb 27, 2025, 3:53 PM EST
WuXi Biologics Revenue
WuXi Biologics had revenue of 8.57B CNY in the half year ending June 30, 2024, with 18.98% growth. This brings the company's revenue in the last twelve months to 17.12B, up 3.40% year-over-year. In the year 2023, WuXi Biologics had annual revenue of 17.03B with 11.56% growth.
Revenue (ttm)
17.12B CNY
Revenue Growth
+3.40%
P/S Ratio
n/a
Revenue / Employee
1.34M CNY
Employees
12,740
Market Cap
12.46B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 17.03B | 1.77B | 11.56% |
Dec 31, 2022 | 15.27B | 4.98B | 48.38% |
Dec 31, 2021 | 10.29B | 4.68B | 83.35% |
Dec 31, 2020 | 5.61B | 1.63B | 40.88% |
Dec 31, 2019 | 3.98B | 1.45B | 57.18% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.79B |
SS Innovations International | 16.04M |
Veradigm | 1.53B |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 188.29M |
Northwest Biotherapeutics | 1.60M |
Silence Therapeutics | 21.77M |
SANUWAVE Health | 29.30M |
WuXi Biologics News
- 10 days ago - WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year - PRNewsWire
- 18 days ago - WuXi Biologics Recognized as ESG Top-Rated Company by Morningstar Sustainalytics - GuruFocus
- 18 days ago - WuXi Biologics Recognized as Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for Fifth Consecutive Year - PRNewsWire
- 5 weeks ago - WuXi Biologics: Spotlight On Property Disposal And Operating Metrics (Rating Upgrade) - Seeking Alpha
- 7 weeks ago - WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million - The Wall Street Journal
- 7 weeks ago - WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million - WSJ
- 7 weeks ago - WuXi Bio to Sell Vaccine Facility to Merck for $500 Million - BNN Bloomberg
- 7 weeks ago - WuXi Biologics Announces Strategic Agreement with Candid Therapeutics - GuruFocus